{
  "id": 16239316,
  "title": "Chinese Drug Shows Benefit in HER2-Low Breast Cancer",
  "url": "https://urgent.news/2026/10/23/chinese-drug-shows-benefit-in-her2-low-breast-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-23T21:13:51.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/esmo/123561"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- An investigational antibody-drug conjugate (ADC) significantly reduced the risk of disease progression or death in patients with HER2-low metastatic breast cancer, a Chinese phase III trial showed. The drug, trastuzumab rezetecan...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}